BKAT Critical Care Practice Exam

Milrinone is primarily classified as a positive inotrope. It works by increasing the contractility of the heart muscle, which enhances the heart's ability to pump blood effectively. This is particularly beneficial in patients with heart failure, where improved cardiac output is essential. Milrinone achieves this positive inotropic effect by inhibiting the enzyme phosphodiesterase-3, leading to an increase in intracellular cyclic adenosine monophosphate (cAMP), which boosts calcium availability and improves myocardial contractility. Additionally, while milrinone does have vasodilatory properties, its primary mechanism and classification relate to its inotropic effects. This differentiates it from medications that primarily focus on lowering blood pressure or providing vasodilation without significantly impacting cardiac contractility. It's important to understand this distinction, especially in a critical care setting where the nuances of heart function and hemodynamics are pivotal to patient management.